Research

Development of steroid sulfatase inhibitors


Reference:

Woo, L. W. L., Purohit, A. and Potter, B. V. L., 2011. Development of steroid sulfatase inhibitors. Molecular and Cellular Endocrinology, 340 (2), pp. 175-185.

Related documents:

[img]
Preview
PDF (Potter_MCE_2011_340_2_175.pdf) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (815kB) | Preview

    Official URL:

    http://dx.doi.org/10.1016/j.mce.2010.12.035

    Abstract

    Hydrolysis of biologically inactive steroid sulfates to unconjugated steroids by steroid sulfatase (STS) is strongly implicated in rendering estrogenic stimulation to hormone-dependent cancers such as those of the breast. Considerable progress has been made in the past two decades with regard to the discovery, design and development of STS inhibitors. We outline historical aspects of their development, cumulating in the discovery of the first clinical trial candidate STX64 (BN83495, Irosustat) and other sulfamate-based inhibitors. The development of reversible STS inhibitors and the design of dual inhibitors of both aromatase and STS is also discussed.

    Details

    Item Type Articles
    CreatorsWoo, L. W. L., Purohit, A. and Potter, B. V. L.
    DOI10.1016/j.mce.2010.12.035
    Uncontrolled Keywordssteroid sulfatase, hormone-dependent breast cancer, enzyme inhibitors, steroid sulfatase inhibitors, dual aromatase and sulfatase inhibitors, review
    DepartmentsFaculty of Science > Pharmacy & Pharmacology
    RefereedYes
    StatusPublished
    ID Code25717

    Export

    Actions (login required)

    View Item

    Document Downloads

    More statistics for this item...